ArticlePediatric health, medicine and therapeutics2025
Pediatric Non-Cystic Fibrosis Pulmonary Nontuberculous Mycobacterium Infections: A Global Population Based Study.
Article in Pediatric health, medicine and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nontuberculous mycobacteria (NTM) are Mycobacterial pathogens that cause pulmonary infections among children, particularly those with underlying lung conditions or immunosuppression. Clinical presentations include chronic cough, weight loss, and fatigue. Diagnosis involves clinical assessment, radiographic imaging, and microbiological confirmation, while treatment often requires prolonged, multidrug antibiotic regimens. This study aimed to analyze the epidemiology and clinical outcomes of pulmonary NTM infections in a non-cystic fibrosis pediatric population from four distinct age groups. Methods: A retrospective study as cross-sectional design for data collection from the TriNetX platform, a global electronic health record database. Inclusion criteria targeted pediatric patients aged 0-18 years with pulmonary NTM, while exclusion criteria included cystic fibrosis, tuberculosis, smoking history, and cutaneous NTM infections. The cohort comprised 109 cases among 0-2 years (mean age 2 years), 401 cases among 3-5 years (mean age 4 years), 1,074 cases among 6-12 years (mean age 9 years), and 760 cases among 13-18 years (mean age 15 years). Demographics, comorbidities, and inflammatory markers were analyzed. Logistic and binomial regression models were used to evaluate associations between age group and five-year outcomes of pediatric pulmonary NTM, reporting odds ratios (OR), risk ratios (RR), 95% confidence intervals (CI), and p-values. Results: Of the total 2,344 records of pediatric patients examined, the most common comorbidities included malignancies (36%), acute pharyngitis (78%), asthma (46%), unspecified pneumonia (46%), and immunodeficiencies (22%). Female patients represented 53.31% of cases. Key inflammatory markers (eg C-reactive protein (CRP), mean white blood cell count, ferritin) were elevated among older age groups. Conclusion: This study highlights age-specific variations in risk factors, clinical outcomes, and inflammatory responses, offering potential insights for improved diagnosis and management of NTM in children. These results underscore the importance of further research in pediatric cohorts with NTM to better understand its role in pediatric pulmonary conditions and comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.